Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bliley Requests FDA Plan To Link Bulk Drug Imports With GMP Compliance

Executive Summary

Rep. Bliley (R-Va.) is asking FDA to formulate a plan to provide import inspectors with access to good manufacturing practices compliance information to determine whether bulk drugs should be detained.

You may also be interested in...



APP Accounts For 1% Of Premier Drug Spend: Response To Times Article

American Pharmaceutical Partners accounts for 1% of drugs purchased by Premier, the company said

APP Accounts For 1% Of Premier Drug Spend: Response To Times Article

American Pharmaceutical Partners accounts for 1% of drugs purchased by Premier, the company said

Bulk Drug Import Quality Reports May Be Required From U.S. Firms

Pharmaceutical manufacturers may be required to notify FDA when they receive bulk drugs of poor quality, FDA Associate Commissioner for Regulatory Affairs Dennis Baker told a House subcommittee hearing June 8.

Related Content

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel